A股異動 | 致遠新能漲7% 擬以6900萬元對江蘇申氫宸進行增資
格隆匯12月6日丨致遠新能(300985.SZ)盤中漲7.65%,報51.67億元,總市值69億元。致遠新能12月5日發佈公吿,公司擬以6900萬元對江蘇申氫宸科技有限公司進行增資;增資完成後,公司將持有江蘇申氫宸30%的股權。標的公司現階段主要產品為燃料電池陽極端核心部件,目前,申氫宸以定製化開發氫能源汽車配件為噴氫器單元、循環泵及組合閥等,主要產品正處在車廠檢驗階段,業務正逐步進入量產階段,主要客户為中弗新能源、東方電氣和捷氫能源等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.